Britta Randlev
Impact in
Papers in
- Co-authors
- David H. Kirn (6 shared papers)John Nemunaitis (5 shared papers)James C. Arseneau (3 shared papers)Ian Ganly (3 shared papers)Fadlo R. Khuri (3 shared papers)Carla Heise (3 shared papers)Martin Gore (1 shared paper)Stanley B. Kaye (1 shared paper)
- Journals
- Gene Therapy (3 papers)Journal of Allergy and Clinical Immunology (2 papers)Journal of Clinical Oncology (1 paper)Cancer Gene Therapy (1 paper)Journal of Virology (1 paper)
- Partner nations
- United StatesUnited KingdomNew Zealand
In The Last Decade
Britta Randlev
14 papers receiving 2.5k citations
Britta Randlev's Hit Papers
Peers
Comparison fields: 5 of 74
- Genetics 2.1k
- Oncology 1.4k
- Biotechnology 475
- Molecular Biology 1.4k
- Otorhinolaryngology 63
Countries citing papers authored by Britta Randlev
This map shows the geographic impact of Britta Randlev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Britta Randlev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Britta Randlev more than expected).
Fields of papers citing papers by Britta Randlev
This network shows the impact of papers produced by Britta Randlev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Britta Randlev. The network helps show where Britta Randlev may publish in the future.
Co-authors
The 25 scholars most cited alongside Britta Randlev, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Hit paper breakdown → | 2000 | 861 |
| 2 | 2001 | 372 | |
| 3 | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. | 2000 | 331 |
| 4 | Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. | 2002 | 253 |
| 5 | 2001 | 228 | |
| 6 | 2001 | 221 | |
| 7 | 2005 | 130 | |
| 8 | 2003 | 71 | |
| 9 | 2005 | 66 | |
| 10 | 1989 | 59 | |
| 11 | 1988 | 6 | |
| 12 | 2010 | 4 | |
| 13 | 1989 | 3 | |
| 14 | 2011 | 2 |
About Britta Randlev
Britta Randlev is a scholar working on Genetics, Oncology, Molecular Biology, Biotechnology and Immunology, having authored 14 papers that have together received 2.6k indexed citations. Recurring topics across this work include Virus-based gene therapy research (9 papers), CAR-T cell therapy research (6 papers), Viral Infectious Diseases and Gene Expression in Insects (3 papers), Cancer Research and Treatments (3 papers), Glycosylation and Glycoproteins Research (1 paper), S100 Proteins and Annexins (1 paper), Immunotherapy and Immune Responses (1 paper) and Chemokine receptors and signaling (1 paper). The work is most often cited by research in Genetics (2.1k citations), Oncology (1.4k citations), Biotechnology (475 citations), Molecular Biology (1.4k citations) and Otorhinolaryngology (63 citations). Britta Randlev has collaborated with scholars based in United States, United Kingdom and New Zealand. Frequent co-authors include David H. Kirn, John Nemunaitis, James C. Arseneau, Ian Ganly, Fadlo R. Khuri, Carla Heise, Martin Gore, Stanley B. Kaye, J. Ironside and Ian F. Tannock. Their work appears in journals such as Gene Therapy, Journal of Allergy and Clinical Immunology, Journal of Clinical Oncology, Cancer Gene Therapy and Journal of Virology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.